Protox received permission to export Protoxin.

According to the Ministry of Food and Drug Safety’s Integrated Drug Information System, product approval was granted for export of Protox ‘Protoxin Injection 100 Units (Clostridium Botulinum Toxin Type A)’ on the 13th.

Protoxin is a botulinum toxin (Botox) that Protoxin is developing in-house, and is being developed as an ATCC3502 strain. Protox is a subsidiary of DSK.

According to the Ministry of Food and Drug Safety, the efficacy is “temporary improvement of moderate to severe glabellar wrinkles related to the activity of the corrugator muscle and/or procerus muscle in adults aged 18 to 65 years.” “It is written as:

Previously, Protox also obtained Phase 1/2 clinical trial (IND) approval and GMP certification for Protoxin injection from the Ministry of Food and Drug Safety on the 31st of last month.

Lee Dae-ho, Money Today Broadcasting MTN reporter